Could this Small Cap Stock really climb 1,846.92% by 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Protect Yourself from Biden's Dollar Destruction...]( [I’ve recorded a short 2 minute message that explains everything here. Simply click here now for all of the details.]( --------------------------------------------------------------- November 3, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"]( The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. [Get the name of the stock here ]( --------------------------------------------------------------- [comScore]( Symbol: [SCOR]( Recent Price: $0.63 Average Analyst Price Target: $12.25 (1,846.92%) Market Cap: $59.48M Last Year's EPS: -$0.13 Consensus EPS Forecast: -$0.01 Expected Earnings Date: Nov 06 2023 Recent Analyst Action: Jason Kreyer, analyst at Craig-Hallum, reiterates coverage on [comScore (SCOR)]( in the Technology sector with a Buy rating and a price target of $23 (1 week ago). [TipRanks.com]( also reports that [comScore]( currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $12.25 . The target pricing ranges from a high forecast of $23 down to a low forecast of $1.5. [comScore (SCOR)](’s last closing price was $0.63 which would put the average price target at 1,846.92% upside. Here are 3rd party ratings for [SCOR](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 35% (162 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Is This the Computing Giant EV's New Power Plant?]( has a code name within the walls of Apple’s Cupertino headquarters — “Project Titan.” Supposedly one of Steve Jobs’ final projects … a new electric vehicle (EV) that would do for the automotive world what the iPhone did for personal devices. The next generation of EVs, including Project Titan, will get their power from a battery the size of your iPhone. [Click HERE for the full story.]( --------------------------------------------------------------- [eFFECTOR Therapeutics]( Symbol: [EFTR]( Recent Price: $0.53 Average Analyst Price Target: $6.58 (1,197.59%) Market Cap: $33.20M Last Year's EPS: -$0.24 Consensus EPS Forecast: -$0.19 Expected Earnings Date: Nov 06 2023 Recent Analyst Action: Robert Burns, analyst at H.C. Wainwright, reiterates coverage on [eFFECTOR Therapeutics (EFTR)]( in the Healthcare sector with a Buy rating and a price target of $5 (2 months ago). [TipRanks.com]( also reports that [eFFECTOR Therapeutics]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.58 . The target pricing ranges from a high forecast of $7 down to a low forecast of $10. [eFFECTOR Therapeutics (EFTR)](’s last closing price was $0.53 which would put the average price target at 1,197.59% upside. Here are 3rd party ratings for [EFTR](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 31% (77 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Durect]( Symbol: [DRRX]( Recent Price: $2.69 Average Analyst Price Target: $29.80 (1,007.81%) Market Cap: $82.25M Last Year's EPS: -$0.52 Consensus EPS Forecast: -$0.45 Expected Earnings Date: Nov 06 2023 Recent Analyst Action: Carl Byrnes, analyst at Northland Securities, reiterates coverage on [Durect (DRRX)]( in the Healthcare sector with a Buy rating and a price target of $12 (1 month ago). [TipRanks.com]( also reports that [Durect]( currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.80 . The target pricing ranges from a high forecast of $41 down to a low forecast of $12. [Durect (DRRX)](’s last closing price was $2.69 which would put the average price target at 1,007.81% upside. Here are 3rd party ratings for [DRRX](: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 37% (92 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [Sunshine Biopharma]( Symbol: [SBFM]( Recent Price: $0.27 Average Analyst Price Target: $2.60 (862.96%) Market Cap: $6.93M Last Year's EPS: -$0.08 Consensus EPS Forecast: - Expected Earnings Date: Nov 06 2023 Recent Analyst Action: David Bouchey, analyst at Aegis Capital, reiterates coverage on [Sunshine Biopharma (SBFM)]( in the Healthcare sector with a Buy rating and a price target of $2.6 (2 months ago). [TipRanks.com]( also reports that [Sunshine Biopharma]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $2.60 . The target pricing ranges from a high forecast of $2.6 down to a low forecast of $2.6. [Sunshine Biopharma (SBFM)](’s last closing price was $0.27 which would put the average price target at 862.96% upside. Here are 3rd party ratings for [SBFM](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- [Forza X1, Inc.]( Symbol: [FRZA]( Recent Price: $0.59 Average Analyst Price Target: $5.00 (750.77%) Market Cap: $8.78M Last Year's EPS: -$0.19 Consensus EPS Forecast: - Expected Earnings Date: Nov 06 2023 Recent Analyst Action: Ashok Kumar, analyst at ThinkEquity, reiterates coverage on [Forza X1, Inc. (FRZA)]( in the Technology sector with a Buy rating and a price target of $5 (1 month ago). [TipRanks.com]( also reports that [Forza X1, Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $5.00 . The target pricing ranges from a high forecast of $5 down to a low forecast of $5. [Forza X1, Inc. (FRZA)](’s last closing price was $0.59 which would put the average price target at 750.77% upside. Here are 3rd party ratings for [FRZA](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Watch SHOCKING Footage of AI Facility with Ties to Elon Musk]( recently traveled more than 3,000 miles and [shot this video outside what could end up being Elon Musk’s biggest secret.]( Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security. [Click here to see the details because this will definitely impact you and your family.]( --------------------------------------------------------------- [Eos Energy Enterprises]( Symbol: [EOSE]( Recent Price: $1.85 Average Analyst Price Target: $11.75 (535.14%) Market Cap: $227.79M Last Year's EPS: -$0.82 Consensus EPS Forecast: -$0.35 Expected Earnings Date: Nov 06 2023 Recent Analyst Action: James West, analyst at Evercore ISI, reiterates coverage on [Eos Energy Enterprises (EOSE)]( in the Energy sector with a Buy rating and a price target of $17 (1 month ago). [TipRanks.com]( also reports that [Eos Energy Enterprises]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.75 . The target pricing ranges from a high forecast of $5 down to a low forecast of $10. [Eos Energy Enterprises (EOSE)](’s last closing price was $1.85 which would put the average price target at 535.14% upside. Here are 3rd party ratings for [EOSE](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 38% (95 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Protalix]( Symbol: [PLX]( Recent Price: $1.69 Average Analyst Price Target: $10.00 (491.72%) Market Cap: $115.96M Last Year's EPS: -$0.05 Consensus EPS Forecast: $0.02 Expected Earnings Date: Nov 06 2023 Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Protalix (PLX)]( in the Healthcare sector with a Buy rating and a price target of $10 (3 days ago). [TipRanks.com]( also reports that [Protalix]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.00 . The target pricing ranges from a high forecast of $10 down to a low forecast of $10. [Protalix (PLX)](’s last closing price was $1.69 which would put the average price target at 491.72% upside. Here are 3rd party ratings for [PLX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The #1 Stock Under $5]( Stock-Picking Millionaire Says It’s Not About Diversification! Buy one single $3 stock- that trades under a secret name- and it could help make your retirement. [His instructions are here.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketMoverAlerts.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. [If you are not a human, click here.]( By opening and/or clicking on any link contained within this email, you are reconfirming your opt-in status. You can unsubsubscribe at any time by clicking on the link in the footer. MarketMoverAlerts.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software